Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty

Drug Design, Development and Therapy

Volumn , Issue 3, 2009, Pages 1-5

  Lewis, Katherine A ^a   Eugster, Erica A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Central precocious puberty; Gonadotropin releasing hormone analogs; Histrelin; Implant

Indexed keywords

HISTRELIN; LUTEINIZING HORMONE;

APPLICATION SITE INFECTION; APPLICATION SITE INFLAMMATION; APPLICATION SITE PAIN; APPLICATION SITE SCAR; BONE MATURATION; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; PRECOCIOUS PUBERTY; QUALITY OF LIFE; REVIEW;

EID: 77953660478     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Nebesio TD, Eugster EA. Current concepts in normal and abnormal puberty. Curr Probl Pediatr Adolesc Health Care. 2007;37(2):50-72.
2. Pescovitz OH, Comite F, Hench K, et al. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy. J Pediatr. 1986;108(1):47-54. (Pubitemid 16126031)
3. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB, Jr. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab. 2001;86(10):4711-4716.
4. Hirsch HJ, Gillis D, Strich D, et al. The histrelin implant: a novel treatment for central precocious puberty. Pediatrics. 2005;116(6):e798-802. (Pubitemid 46056458)
5. Dineen MK, Tierney DS, Kuzma P, Pentikis HS. An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer. J Clin Pharmacol. 2005;45(11):1245- 1249. (Pubitemid 41513047)
6. Chertin B, Spitz IM, Lindenberg T, et al. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer. J Urol. 2000;163(3):838-844. (Pubitemid 30091628)
7. Schlegel PN, Kuzma P, Frick J, et al. Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin. Urology. 2001;58(4):578-582. (Pubitemid 32904502)
8. Schlegel PN. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer. J Urol. 2006;175(4):1353-1358.
9. Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab. 2007;92(5):1697-1704. (Pubitemid 46997174)
10. Rahhal S CW, Kletter GB, Lee PA, et al. Results of a second year of therapy with the 12 month histrelin implant for the treatment of central precocious puberty. 2008; Abstract for oral presentation at the Pediatric Academic Society Annual Meeting.
11. Olsen J. New Drug Bulletin: Histrelin (Supprelin LA - Indevus). Available from http://uuhsc.utah.edu/pharmacy/bulletins/NDB-153.pdf.
12. Feuillan PP, Jones JV, Barnes K, Oerter-Klein K, Cutler GB, Jr. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metab. 1999;84(1):44-49. (Pubitemid 29036678)
13. Bertelloni S, Mul D. Treatment of central precocious puberty by GnRH analogs: long-term outcome in men. Asian J Androl. 2008;10(4):525-534. (Pubitemid 351865758)
14. Bertelloni S, Baroncelli GI, Ferdeghini M, Menchini-Fabris F, Saggese G. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues. Eur J Pediatr. 2000; 159(5):369-374. (Pubitemid 30243642)
15. Kunz GJ, Sherman TI, Klein KO. Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment? J Pediatr Endocrinol Metab. 2007;20(11):1189-1198.
16. Carel JC EE, Rogol A, Ghizzoni L, Palmert M. on behalf of the ESPELWPES GnRH analogs consensus conference group. Consensus statement on the use of GnRH analogs in children. Pediatrics. In press.